ReviewFrontiers in medicine2025
Clinical manifestations and outcomes of HSK following corneal transplantation.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the clinical manifestations and outcomes of herpes simplex keratitis (HSK) infection following corneal transplantation. Methods: This retrospective study analyzed medical records of patients who underwent corneal transplantation at the People's Hospital of Guangxi Zhuang Autonomous Region between January 2018 and March 2024, with a minimum follow-up period of 1 year. The study examined post-transplantation herpes simplex virus (HSV) infections, including the timing of HSV infection, HSK classification, clinical manifestations, and outcomes. Results: A total of 411 patients (corresponding to 411 eyes) were followed up. Among them, 88 cases (21.41% of the 411 cases) were diagnosed with or suspected of HSK before corneal transplantation. Of these 88 cases, 13 cases (14.77% of the 88 cases) developed recurrent HSK after surgery (8 cases underwent corneal transplantation during the acute phase, and 5 cases during the scarring phase). There were 323 cases with no evidence of HSK before corneal transplantation, among which 27 cases (8.36% of the 323 cases) developed new-onset HSK after corneal transplantation. Among all 411 patients, a total of 40 cases (9.73% of the 411 cases) developed HSK after corneal transplantation, with 26 cases (26 eyes) (65% of the 40 cases) developing HSK within 1-3 months post-surgery. Regarding HSK types, epithelial HSK occurred in 11 cases (27.5% of the 40 cases), all of which achieved corneal transparency with regular use of antiviral medication. Stromal necrotizing HSK occurred in 8 cases (20% of the 40 cases), with 2 cases developing corneal nebula, 5 cases developing corneal macula, and 1 case requiring repeat corneal transplantation due to near-perforation. Combined epithelial, stromal, and endothelial HSK occurred in 17 cases (42.5% of the 40 cases), with 1 case developing corneal nebula, 4 cases developing corneal macula, 10 cases developing corneal leucoma, and 2 cases requiring repeat corneal transplantation due to corneal perforation. Endothelial HSK occurred in 4 cases (10% of the 40 cases), with 2 cases achieving grade 0 corneal transparency and 2 cases achieving grade 2 corneal transparency. Conclusion: The first 1-3 months following corneal transplantation is a peak time for HSK. Regular follow-up is essential for all patients post-surgery. For those with a history of HSK, vigilance for HSK is critical, while timely diagnosis and differentiation of HSK are crucial for non-HSK patients. When administering systemic antiviral therapy, it is important to adjust the frequency and intensity of steroid treatments promptly to prevent irreversible graft opacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.